KR20220084641A - Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient - Google Patents
Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient Download PDFInfo
- Publication number
- KR20220084641A KR20220084641A KR1020200174316A KR20200174316A KR20220084641A KR 20220084641 A KR20220084641 A KR 20220084641A KR 1020200174316 A KR1020200174316 A KR 1020200174316A KR 20200174316 A KR20200174316 A KR 20200174316A KR 20220084641 A KR20220084641 A KR 20220084641A
- Authority
- KR
- South Korea
- Prior art keywords
- baechohyang
- preventing
- extract
- fraction
- diabetes
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 240000004510 Agastache rugosa Species 0.000 title claims abstract description 18
- 235000010686 Agastache rugosa Nutrition 0.000 title claims abstract description 18
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 31
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 30
- 239000002034 butanolic fraction Substances 0.000 claims abstract description 7
- 239000002038 ethyl acetate fraction Substances 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 37
- 239000002904 solvent Substances 0.000 claims description 35
- 235000013376 functional food Nutrition 0.000 claims description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 28
- 230000036541 health Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000796 flavoring agent Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 238000005194 fractionation Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 14
- 230000002265 prevention Effects 0.000 abstract description 5
- 235000000346 sugar Nutrition 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 235000013305 food Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 7
- 229960002632 acarbose Drugs 0.000 description 7
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 7
- 102000004139 alpha-Amylases Human genes 0.000 description 7
- 108090000637 alpha-Amylases Proteins 0.000 description 7
- 229940024171 alpha-amylase Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 pH adjusters Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102400000471 Isomaltase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 108010026867 Oligo-1,6-Glucosidase Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KTUQUZJOVNIKNZ-UHFFFAOYSA-N butan-1-ol;hydrate Chemical compound O.CCCCO KTUQUZJOVNIKNZ-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/18—Fractionation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물에 관한 것으로서, 본 발명의 배초향 분획물은, 혈당 증가와 관련된 효소인 알파-글루코시데이즈를 효과적으로 억제할 수 있고, 특히 에틸아세테이트 분획물 및 n-부탄올 분획물의 알파-글루코시데이즈억제 효과가 우수한 것을 확인하여, 당뇨병의 예방 또는 치료에 유용하게 사용할 수 있는 것을 확인하여 관련 산업에 유용하게 이용할 수 있다.The present invention relates to a composition for preventing or treating diabetes comprising an Agastache rugosa fraction as an active ingredient. , In particular, it is confirmed that the alpha-glucosidase inhibitory effect of the ethyl acetate fraction and the n-butanol fraction is excellent, and it can be usefully used in related industries by confirming that it can be usefully used for the prevention or treatment of diabetes.
Description
본 발명은, 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병의 예방 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing or treating diabetes comprising a baechohyang fraction as an active ingredient.
당뇨병은 고혈당을 특징으로 하는 일련의 대사 질환군으로 만성적인 고혈당은 적절한 치료를 하지 않으면 대혈관합병증, 미세혈관합병증, 당뇨병성 신경병증 및 신장 질환과 같은 합병증을 야기하게 된다. 당뇨병은 크게 두 가지 유형으로 구분되는데, 제1형 당뇨병 (type 1 diabetes mellitus)은 혈액 내의 포도당 조절 호르몬인 인슐린의 분비 결핍으로 야기되며, 주로 10 내지 20대의 젊은 연령층에서 발병되기 때문에 소아 당뇨병 (juvenile diabetes)이라 불리기도 한다. 제2형 당뇨병 (type 2 diabetes mellitus)은 주로 40대 이후에 발병되며, 우리나라 당뇨병 환자의 대부분을 차지한다. 제1형과는 달리 성인형 당뇨병이라 불리며 발병 원인은 아직 명확히 밝혀져 있지 않으나, 유전적인 요인과 환경적 요소가 함께 관여되어 발생하는 것으로 알려져 있다. 제2형 당뇨병의 병인으로 췌장베타세포에서 인슐린 분비의 장애와 표적세포에서 인슐린 작용의 결함 (인슐린 저항성)이 모두 관찰된다. 현재까지 당뇨병의 완치법은 확립되어 있지 않고, 경구용 혈당 강하제는 다양한 부작용이 보고되고 있으므로 보다 안전한 제2형 당뇨병 치료제의 개발에 관심이 모아지고 있다.Diabetes mellitus is a group of metabolic diseases characterized by high blood sugar, and chronic high blood sugar causes complications such as macrovascular complications, microvascular complications, diabetic neuropathy and kidney disease if not properly treated. Diabetes is largely divided into two types.
한편, 알파-글루코시데이스(α-glucosidase)는 탄수화물을 가수분해하여 알파-글루코오스를 생성하는 분해효소로서, 유기체에 필수적인 에너지 공급을 위한 당을 제공한다. 인간에서는 알파-글루코시데이스가 탄수화물 분해의 마지막 단계에서 작용하기 때문에, 알파-글루코시데이스 매개 혈당의 생성은 건강한 상태를 유지하기 위해 체내에 에너지를 공급한다. 알파-글루코시데이스의 농도가 낮을 경우 폼페병(Pompe's disease), 및 리소좀의 알파-글루코시데이스 결핍에 의해 야기되는 글리코겐 저장 장애와 같은 심각한 병리학적 변화가 나타나며, 이와 대조적으로, 상기 효소의 활성이 높은 경우에는 혈당 수치가 증가할 수 있고, 결과적으로 제2형 당뇨를 가진 환자들에서 포도당 흡수에 심각한 영향을 미칠 수 있다.On the other hand, alpha-glucosidase is a degrading enzyme that hydrolyzes carbohydrates to produce alpha-glucose, and provides sugar for essential energy supply to organisms. In humans, alpha-glucosidase acts in the final stage of carbohydrate breakdown, so the production of alpha-glucosidase-mediated blood sugar supplies the body with energy to maintain a healthy state. When the concentration of alpha-glucosidase is low, serious pathological changes such as Pompe's disease and impaired glycogen storage caused by alpha-glucosidase deficiency in the lysosome, in contrast, occur, in contrast, the activity of the enzyme When this is high, blood sugar levels can rise, which can seriously affect glucose uptake in patients with type 2 diabetes.
당뇨병 환자의 경우, 탄수화물과 같은 음식물을 섭취하였을 때 식후 2시간이내에 급격하게 혈당이 올라가게 된다. 이러한 급격한 식후 혈당 상승을 막아주는 물질로 알려진 것이 바로 알파-글루코시다아제 저해제(α-glucosidase inhibitor)이다. 일반적으로 알파-글루코시다아제 저해제는 소장내 이당류 분해효소인 말타아제(maltase), 수크라제(sucrase) 및 이소말타아제(isomaltase) 등의 소화작용을 억제하여 체내로 혈당이 급격하게 들어오는 것을 억제해주는 물질로 알려져 있다. 이러한 알파-글루코시다아제 저해제로 상품화된 물질로는 아카보스(acarbose), 보글리보즈(voglibose) 및 미글리톨(miglitol) 등이 있다.In the case of diabetic patients, when food such as carbohydrates is ingested, blood sugar rises rapidly within 2 hours after a meal. Alpha-glucosidase inhibitors are known as substances that prevent such rapid postprandial blood sugar rise. In general, alpha-glucosidase inhibitors are substances that inhibit the rapid influx of blood sugar into the body by inhibiting the digestive action of maltase, sucrase, and isomaltase, which are disaccharide decomposing enzymes in the small intestine. is known as Materials commercialized as such alpha-glucosidase inhibitors include acarbose, voglibose, and miglitol.
그러나, 생약 성분이 알파-글루코시데이즈의 활성을 억제시키는지 확인하고자 하는 연구는 미비한 실정이며, 이에 본 발명자들은 배초향 분획물이, 효과적으로 알파-글루코시데이즈의 활성을 억제시키는 것을 확인하여, 본 발명을 완성하였다. However, studies to ascertain whether herbal ingredients inhibit the activity of alpha-glucosidase are insufficient. Accordingly, the present inventors confirmed that the baecho-hyang fraction effectively inhibits the activity of alpha-glucosidase, and the present invention was completed.
본 발명의 목적은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.It is an object of the present invention to provide a health functional food composition for preventing or improving diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
본 발명의 다른 목적은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
본 발명의 또 다른 목적은 1) 배초향(Agastache rugosa)을 건조시키는 단계;Another object of the present invention is 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 개선용 건강기능식품 조성물의 제조 방법을 제공하는 것이다.3) to provide a method for preparing a health functional food composition for preventing or improving diabetes, including; 3) fractionating the baechohyang extract of step 2) with a fractionation solvent.
본 발명의 또 다른 목적은 1) 배초향(Agastache rugosa)을 건조시키는 단계;Another object of the present invention is 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물의 제조 방법을 제공하는 것이다.3) to provide a method for preparing a pharmaceutical composition for the prevention or treatment of diabetes, including the step of fractionating the baechohyang extract of step 2) with a fractionation solvent.
본 발명은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or improving diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
또한, 본 발명은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
또한, 본 발명은 1) 배초향(Agastache rugosa)을 건조시키는 단계;In addition, the present invention 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 개선용 건강기능식품 조성물의 제조 방법을 제공한다.It provides a method for preparing a health functional food composition for preventing or improving diabetes, including; 3) fractionating the baechohyang extract of step 2) with a fractionation solvent.
또한, 본 발명은 1) 배초향(Agastache rugosa)을 건조시키는 단계;In addition, the present invention 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물의 제조 방법을 제공한다.3) fractionating the baechohyang extract of step 2) with a fractionation solvent; provides a method for preparing a pharmaceutical composition for preventing or treating diabetes, including.
본 발명의 배초향(Agastache rugosa) 분획물은, 혈당 증가와 관련된 효소인 알파-글루코시데이즈를 효과적으로 억제할 수 있고, 특히 에틸아세테이트 분획물 및 n-부탄올 분획물의 알파-글루코시데이즈 억제 효과가 우수한 것을 확인하여, 당뇨병의 예방 또는 치료에 유용하게 사용할 수 있는 것을 확인하여 관련 산업에 유용하게 이용할 수 있다.The baechohyang ( Agastache rugosa ) fraction of the present invention can effectively inhibit alpha-glucosidase, an enzyme associated with an increase in blood sugar, and in particular, it is confirmed that the ethyl acetate fraction and n-butanol fraction have excellent alpha-glucosidase inhibitory effects. Thus, it can be usefully used in related industries by confirming that it can be usefully used for the prevention or treatment of diabetes.
도 1은 본 발명의 배초향 추출물의 선별을 위해 알파-글루코시데이즈 활성 억제를 평가한 것이다.
도 2는 본 발명의 배초향 추출물의 선별을 위해 알파-아밀레이즈 활성 억제를 평가한 것이다.
도 3은 본 발명의 배초향 추출물을 분획하는 과정을 도식화한 것이다.
도 4는 본 발명의 배초향 분획물의 알파-글루코시데이즈 활성 억제를 확인한 것이다.1 is an evaluation of the inhibition of alpha-glucosidase activity for the selection of the baechohyang extract of the present invention.
Figure 2 is an evaluation of the inhibition of alpha-amylase activity for the selection of the baechohyang extract of the present invention.
Figure 3 is a schematic diagram of the process of fractionating the baechohyang extract of the present invention.
Figure 4 confirms the inhibition of alpha-glucosidase activity of the baechohyang fraction of the present invention.
본 발명은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 개선용 건강기능식품 조성물을 제공한다.The present invention provides a health functional food composition for preventing or improving diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
본 발명에서 사용되는 용어 “예방”은 본 발명의 조성물의 투여로 특정 질환의 증상을 억제하거나 진행을 지연시키는 모든 행위를 의미한다.As used herein, the term “prevention” refers to any action that suppresses the symptoms of a specific disease or delays the progression by administration of the composition of the present invention.
본 발명에서 사용되는 용어 “개선”은 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.As used herein, the term “improvement” refers to any action that at least reduces a parameter related to a condition to be treated, for example, the severity of symptoms.
본 발명의 식품 조성물은 본 발명의 유효성분을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a conventional food composition.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 본 발명의 식품 조성물은 상기 약학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-mentioned flavoring agents can advantageously use natural flavoring agents (Taumatine), stevia extract (eg rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements. There is this.
또한 상기 식품 조성물은 유효성분인 추출물 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the food composition includes, in addition to the active ingredient extract, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages.
본 발명의 기능성 식품 조성물은 당뇨병의 예방 또는 치료 목적으로, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공될 수 있다. 본 발명에서 '건강기능성 식품 조성물'이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. 본 발명의 건강기능식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전청에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 '식품 첨가물 공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다. 예를 들어, 정제 형태의 건강기능식품은 본 발명의 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강기능식품은 필요에 따라 교미제 등을 함유할 수도 있다. 캅셀 형태의 건강기능식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다. 환 형태의 건강기능식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다. 과립 형태의 건강기능식품은 본 발명의 유효성분의 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing or treating diabetes. In the present invention, the term 'health functional food composition' refers to food manufactured and processed using raw materials or ingredients useful for the human body according to Act No. 6727 of the Health Functional Food Act, and It refers to ingestion for the purpose of obtaining useful effects for health purposes, such as regulating nutrients or physiological effects. The health functional food of the present invention may contain normal food additives, and unless otherwise specified, whether it is suitable as a food additive is related to the item according to the general rules and general test method of food additives approved by the Food and Drug Administration. It is judged according to the standards and standards. The items listed in the 'Food Additives Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, a noodle-added alkali agent, a preservative preparation, and a tar color preparation, etc. are mentioned. For example, a health functional food in tablet form is granulated by a conventional method by mixing a mixture of the active ingredient of the present invention with an excipient, binder, disintegrant and other additives, followed by compression molding by putting a lubricant, etc., or The mixture can be compression molded directly. In addition, the health functional food in the form of tablets may contain a corrosive agent and the like, if necessary. Among health functional foods in capsule form, hard capsules can be prepared by filling a mixture of the active ingredient of the present invention with additives such as excipients in a conventional hard capsule. It can be prepared by filling the mixture mixed with the capsule base such as gelatin. The soft capsules may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary. A health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, etc. by a known method, Alternatively, the surface may be coated with a material such as starch or talc. The health functional food in the form of granules can be prepared in granular form by a conventionally known method by mixing a mixture of the active ingredient excipients, binders, disintegrants, etc. of the present invention, and may contain flavoring agents, flavoring agents, etc. as needed can
본 발명의 일실시예에 따르면, 상기 배초향 분획물은 배초향 추출물로부터 분획되는 것일 수 있다.According to an embodiment of the present invention, the baechohyang fraction may be fractionated from baechohyang extract.
본 발명의 일실시예에 따르면, 상기 배초향 추출물은 물, C1 내지 C4의 저급 알코올 또는 저급 알코올 수용액으로 추출되는 것일 수 있다.According to an embodiment of the present invention, the baechohyang extract may be extracted with water, C1 to C4 lower alcohol or lower alcohol aqueous solution.
본 발명의 일실시예에 따르면, 상기 배초향 분획물은 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 클로로포름, 헥산 및 에틸아세테이트로 이루어진 군에서 선택된 용매로 분획되는 것일 수 있으며, 바람직하게는 에틸아세테이트 또는 n-부탄올이나, 이에 제한되지는 않는다.According to an embodiment of the present invention, the baecho flavor fraction may be fractionated with a solvent selected from the group consisting of water, C1 to C4 lower alcohol, lower alcohol aqueous solution, chloroform, hexane and ethyl acetate, preferably ethyl acetate or n-butanol, but is not limited thereto.
본 발명의 일실시예에 따르면, 상기 배초향 분획물은 알파-글루코시데이즈(α-glucosidase)의 활성을 억제시키는 것일 수 있다.According to one embodiment of the present invention, the baechohyang fraction may be to inhibit the activity of alpha-glucosidase (α-glucosidase).
또한, 본 발명은 배초향(Agastache rugosa) 분획물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating diabetes comprising a baechohyang ( Agastache rugosa ) fraction as an active ingredient.
본 발명에서 사용되는 용어 “치료”는 본 발명의 조성물의 투여로 특정 질환의 증상을 호전 또는 이롭게 변경시키는 모든 행위를 의미한다.As used herein, the term “treatment” refers to any action that improves or beneficially changes the symptoms of a specific disease by administration of the composition of the present invention.
본 발명의 약학 조성물에는 유효성분 이외에 보조제(adjuvant)를 추가로 포함할 수 있다. 상기 보조제는 당해 기술분야에 알려진 것이라면 어느 것이나 제한 없이 사용할 수 있으나, 예를 들어 프로인트(Freund)의 완전 보조제 또는 불완전 보조제를 더 포함하여 그 효과를 증가시킬 수 있다.The pharmaceutical composition of the present invention may further include an adjuvant in addition to the active ingredient. The adjuvant may be used without limitation as long as it is known in the art, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase the effect.
본 발명에 따른 약학 조성물은 유효성분을 약학적으로 허용된 담체에 혼입시킨 형태로 제조될 수 있다. 여기서, 약학적으로 허용된 담체는 제약 분야에서 통상 사용되는 담체, 부형제 및 희석제를 포함한다. 본 발명의 약학 조성물에 이용할 수 있는 약학적으로 허용된 담체는 이들로 제한되는 것은 아니지만, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition according to the present invention may be prepared in a form in which the active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀전, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injection solutions according to conventional methods, respectively. .
제제화할 경우에는 통상 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 그러한 고형 제제는 유효성분에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카르보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 일반적으로 사용되는 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수용성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수용성용제, 현탁제로는 프로필렌 글리콜, 폴리에틸렌 글리콜, 올리브유와 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.In the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. commonly used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the active ingredient, for example, starch, calcium carbonate, sucrose, lactose, gelatin. It can be prepared by mixing and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used diluents, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. can Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As the base of the suppository, witepsol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.
본 발명에 따른 약학 조성물은 개체에 다양한 경로로 투여될 수 있다. 투여의 모든 방식이 예상될 수 있는데, 예를 들면 경구, 정맥, 근육, 피하, 복강내 주사에 의해 투여될 수 있다.The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration can be envisaged, for example, by oral, intravenous, intramuscular, subcutaneous, intraperitoneal injection.
본 발명에 따른 약학 조성물의 투여량은 개체의 연령, 체중, 성별, 신체 상태 등을 고려하여 선택된다. 상기 약학 조성물 중 포함되는 유효성분의 농도는 대상에 따라 다양하게 선택할 수 있음은 자명하며, 바람직하게는 약학 조성물에0.01 ~ 5,000 ㎍/ml의 농도로 포함되는 것이다. 그 농도가 0.01 ㎍/ml 미만일 경우에는 약학 활성이 나타나지 않을 수 있고, 5,000 ㎍/ml를 초과할 경우에는 인체에 독성을 나타낼 수 있다.The dosage of the pharmaceutical composition according to the present invention is selected in consideration of the individual's age, weight, sex, physical condition, and the like. It is self-evident that the concentration of the active ingredient included in the pharmaceutical composition can be variously selected depending on the subject, and is preferably included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg/ml. If the concentration is less than 0.01 μg/ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg/ml, it may be toxic to the human body.
또한, 본 발명은 1) 배초향(Agastache rugosa)을 건조시키는 단계;In addition, the present invention 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 개선용 건강기능식품 조성물의 제조 방법을 제공한다.It provides a method for preparing a health functional food composition for preventing or improving diabetes, including; 3) fractionating the baechohyang extract of step 2) with a fractionation solvent.
또한, 본 발명은 1) 배초향(Agastache rugosa)을 건조시키는 단계;In addition, the present invention 1) drying the baechohyang ( Agastache rugosa );
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물의 제조 방법을 제공한다.3) fractionating the baechohyang extract of step 2) with a fractionation solvent; provides a method for preparing a pharmaceutical composition for preventing or treating diabetes, including.
이하, 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 이들 실시예는 단지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 국한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail by way of Examples. These examples are merely for illustrating the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited to these examples.
<실시예 1>배초향 추출물의 제조 및 선별<Example 1> Preparation and selection of baechohyang extract
<1-1>배초향 추출물의 제조<1-1> Preparation of baechohyang extract
본 발명의 배초향 분획물을 제조하기 위하여, 우선적으로 배초향 추출물을 제조하였다. 구체적으로 배초향 지상부)를 동결건조기(PVTFD 50R, Ilshinbio, Seoul, KOREA)로 건조하여 분말화 하였다. 추출을 위해 건조된 배초향에 1 : 10의 부피비로 용매를 첨가하여, 지상부 50 g을 70% 에탄올 또는 물을 용매로 추출하였다. 배초향 지상부 50 g에 용매 500 ml을 첨가하여, 실온에서 24시간 동안 추출하였다. 상기 추출과정을 3번 반복하였으며, 추출 여액은 여과해서 농축하고 동결건조 하였다. 각 추출물은 100mg/ml의 농도로 다이메틸설폭사이드(Dimethylsulfoxide, DMSO)에 녹여 희석하여 사용하였다.In order to prepare the baechohyang fraction of the present invention, a baechohyang extract was preferentially prepared. Specifically, the above-ground portion of baechohyang) was dried and powdered with a freeze dryer (PVTFD 50R, Ilshinbio, Seoul, KOREA). For extraction, a solvent was added in a volume ratio of 1:10 to dried baechohyang, and 50 g of the above-ground part was extracted with 70% ethanol or water as a solvent. 500 ml of solvent was added to 50 g of baechohyang above ground, and extracted at room temperature for 24 hours. The extraction process was repeated 3 times, and the extraction filtrate was concentrated by filtration and freeze-dried. Each extract was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mg/ml and used after dilution.
<1-2>배초향 추출물의 선별<1-2> Selection of baechohyang extract
상기 실시예 1-1에서 제조된 배초향 추출물을 이용하여, 혈당과 관련된 효소인, 알파-글루코시데이즈(α-glucosidase)의 활성을 억제하는지 확인하고자 하였다. 구체적으로, 알파-글루코시데이즈의 활성을 측정하기 위하여, α-glucosidase 활성 비색 분석 키트(biovision, Milpitas,CA, USA)를 이용하였다. 상기 실시예 1-1의 배초향 추출물을 각각 0.25, 0.5, 1 mg/ml의 농도로 희석한 샘플을 96 well 플레이트의 well에 10 μl씩 넣고, 분석 완충액을 60 μl 첨가 후 10 μl의 α-glucosidase를 첨가하여, 실온에서 빛을 차단하여 30분간 반응시켰다. 그 후 20 μl의 α-glucosidase 기질 혼합물을 각 well에 첨가한 후 마이크로플레이트 리더(microplate reader, Biotek, Winooski, VT, USA)에서 410 nm에서 40분간 kinetic mode로 흡광도를 측정하였다. 양성대조군으로는 아카보스(acarbose)를 1 mg/ml의 농도로 사용하였다.Using the baechohyang extract prepared in Example 1-1, it was attempted to confirm whether the activity of alpha-glucosidase, an enzyme related to blood sugar, was inhibited. Specifically, in order to measure the activity of alpha-glucosidase, an α-glucosidase activity colorimetric assay kit (biovision, Milpitas, CA, USA) was used. 10 μl of each diluted sample of the baechohyang extract of Example 1-1 to a concentration of 0.25, 0.5, and 1 mg/ml was put into each well of a 96-well plate, and after adding 60 μl of analysis buffer, 10 μl of α-glucosidase was added, and the light was blocked at room temperature and reacted for 30 minutes. After that, 20 μl of the α-glucosidase substrate mixture was added to each well and absorbance was measured in kinetic mode at 410 nm for 40 minutes in a microplate reader (microplate reader, Biotek, Winooski, VT, USA). As a positive control, acarbose was used at a concentration of 1 mg/ml.
또한, 혈당과 관련된 효소인, 알파-아밀레이즈(α-amylase)의 활성을 측정하기 위하여, α-amylase 활성 비색 분석 키트(biovision, Milpitas,CA, USA)를 이용하였다. 구체적으로, 상기 실시예 1-1의 배초향 추출물을 각각 0.25, 0.5, 1 mg/ml의 농도로 96 well 플레이트의 well에 50 μl씩 넣고, 50 μl의 알파-아밀레이즈를 첨가하여 실온에서 빛을 차단하여 10분간 반응시켰다. 그 후 50 μl의 알파-아밀레이즈 기질 혼합물을 각 well에 첨가한 후 마이크로플레이트 리더(microplate reader, Biotek, Winooski, VT, USA)에서 405 nm에서 20분간 kinetic mode로 흡광도를 측정하였다. 양성대조군으로는 아카보스(acarbose)를 1 mg/ml의 농도로 사용하였다.In addition, to measure the activity of α-amylase, an enzyme related to blood sugar, an α-amylase activity colorimetric assay kit (biovision, Milpitas, CA, USA) was used. Specifically, 50 μl of the baechohyang extract of Example 1-1 was put into wells of a 96-well plate at a concentration of 0.25, 0.5, and 1 mg/ml, respectively, and 50 μl of alpha-amylase was added to light at room temperature. Blocked and reacted for 10 minutes. After that, 50 μl of alpha-amylase substrate mixture was added to each well, and absorbance was measured in kinetic mode at 405 nm for 20 minutes in a microplate reader (microplate reader, Biotek, Winooski, VT, USA). As a positive control, acarbose was used at a concentration of 1 mg/ml.
그 결과, 도 1에 나타낸 바와 같이, 알파-글루코시데이즈 억제 효과는 양성대조군인 아카보스에서 1 mg/ml의 농도에서 74.2%의 억제 효과를 보였으며, 배초향 물 추출물은 1 mg/ml의 농도에서 27.5% 억제 효과를 보였고, 배초향 70% 주정 추출물은 1 mg/ml의 농도에서 34.6% 억제효과를 나타낸 것을 확인하였다.As a result, as shown in FIG. 1 , the alpha-glucosidase inhibitory effect was 74.2% inhibitory at a concentration of 1 mg/ml in acarbose, a positive control, and the baechohyang water extract at a concentration of 1 mg/ml. It was confirmed that 27.5% inhibitory effect was shown, and the 70% alcohol extract of baechohyang showed a 34.6% inhibitory effect at a concentration of 1 mg/ml.
또한 도 2에 나타낸 바와 같이, 알파-아밀레이즈 억제 효과는 양성 대조군인 아카보스에서 1 mg/ml의 농도에서 96.6% 억제 효과를 보였으며, 배초향 물 추출물은 농도가 증가하여도 농도에 따라 유의미한 차이를 나타내지 않았으며 1 mg/ml의 농도에서 0.84%인 것을 확인하였다. 반면, 70% 주정 추출물은 1 mg/ml의 농도에서 68.8%의 억제효과를 가지는 것을 확인하였다.In addition, as shown in FIG. 2 , the alpha-amylase inhibitory effect showed a 96.6% inhibitory effect at a concentration of 1 mg/ml in acarbose, a positive control, and the baechohyang water extract showed a significant difference depending on the concentration even as the concentration increased. It was not shown and it was confirmed that it was 0.84% at a concentration of 1 mg/ml. On the other hand, it was confirmed that the 70% alcohol extract had an inhibitory effect of 68.8% at a concentration of 1 mg/ml.
따라서, 배초향 추출물 중 70% 주정 추출물이 혈당과 관련된 효소인 알파-글루코시데이즈 및 알파-아밀레이즈의 활성 억제효과가 우수한 것을 확인 하여, 추후 실험은 배초향 70% 주정 추출물을 이용하여 수행하였다.Therefore, it was confirmed that the 70% alcohol extract of the baechohyang extract had excellent inhibitory effect on the activity of alpha-glucosidase and alpha-amylase, which are enzymes related to blood sugar, and subsequent experiments were performed using the 70% alcohol extract of the baechohyang extract.
<실시예 2> 배초향 분획물의 제조<Example 2> Preparation of baechohyang fraction
상기 실시예 1-2에서 선별된 배초향 70% 주정 추출물을 이용하여 배초향 분획물을 제조하였다. 구체적으로 배초향 추출물의 순차적인 분획을 위해, 배초향 70% 주정 추출물 1 g을 물 200 ml에 재용해 한 후 분획 깔데기(separatory funnel)에 넣고, 헥산(hexane), 클로로포름(chloroform), 에틸아세테이트(ehtyl acetate), 물(water) 및 n-부탄올(n-butanol)의 순서로 가하여 분획하였다(도 3). 분획 후 남은 물층을 포함하여 5개의 분획물은 감암농축한 후 DMSO에 재용해 하여 시료로 사용하였다. 각 용매별 수율은 n-부탄올 11.2%, 헥산 9%, 클로로포름 5.9%, 에틸아세테이트 4.7% 및 물 59.9%로 확인되었다.A baechohyang fraction was prepared using the 70% baechohyang alcohol extract selected in Example 1-2. Specifically, for the sequential fractionation of baechohyang extract, 1 g of baechohyang 70% alcohol extract is redissolved in 200 ml of water and put in a separation funnel, hexane, chloroform, ethyl acetate (ehtyl) acetate), water, and n-butanol were added in the order of fractionation (FIG. 3). Five fractions, including the water layer remaining after fractionation, were concentrated under reduced pressure and then re-dissolved in DMSO to be used as samples. The yield for each solvent was confirmed to be n-butanol 11.2%, hexane 9%, chloroform 5.9%, ethyl acetate 4.7%, and water 59.9%.
<실시예 3> 배초향 분획물의 알파-글루코시데이즈 활성 억제 확인<Example 3> Confirmation of inhibition of alpha-glucosidase activity of baechohyang fraction
상기 실시예 2에서 분획된 각각의 분획물은, 실시예 1-2의 방법으로 알파-글루코시데이즈 활성을 측정하였다. 대조군으로는 아카보스를 1 mg/ml의 농도로 사용하였다.For each fraction fractionated in Example 2, alpha-glucosidase activity was measured by the method of Example 1-2. As a control, acarbose was used at a concentration of 1 mg/ml.
그 결과, 도 4에 나타낸 바와 같이, 알파-글루코시데이즈 활성 억제는 대조군인 아카보스는 1 mg/ml의 농도에서 86.7%인 것을 확인하였으며, 순차적으로 에틸아세테이트 분획물(77.7%), n-부탄올 분획물(76.4%), 물 분획물(41.6%)순으로 알파-글루코시데이즈 활성을 억제하는 것을 확인하였으며, 클로로포름 분획물 및 헥산 분획물은 알파-글루코시데이즈 활성 억제력(각각 0%)이 없는 것을 확인하였다. 따라서, 본 발명의 배초향 분획물 중 에틸아세테이트 분획물 및 n-부탄올 분획물이 알파-글루코시데이즈 활성 억제가 우수한 것을 확인하였다.As a result, as shown in FIG. 4 , it was confirmed that acarbose, a control, was 86.7% at a concentration of 1 mg/ml for inhibition of alpha-glucosidase activity, and sequentially an ethyl acetate fraction (77.7%) and an n-butanol fraction (76.4%) and the water fraction (41.6%) were confirmed to inhibit alpha-glucosidase activity in that order, and it was confirmed that the chloroform fraction and hexane fraction had no inhibitory ability (each 0%) of alpha-glucosidase activity. Therefore, it was confirmed that the ethyl acetate fraction and the n-butanol fraction among the baechohyang fractions of the present invention were excellent in inhibiting alpha-glucosidase activity.
따라서 본 발명의 배초향 분획물은, 혈당 증가와 관련된 효소인 알파-글루코시데이즈를 효과적으로 억제할 수 있고, 특히 에틸아세테이트 분획물 및 n-부탄올 분획물의 알파-글루코시데이즈 억제 효과가 우수한 것을 확인하여, 당뇨병의 예방 또는 치료에 유용하게 사용할 수 있는 것을 확인하였다.Therefore, the baecho-hyang fraction of the present invention can effectively inhibit alpha-glucosidase, an enzyme associated with an increase in blood sugar, and in particular, it was confirmed that the ethyl acetate fraction and the n-butanol fraction had excellent alpha-glucosidase inhibitory effects. It was confirmed that it can be usefully used for the prevention or treatment of
Claims (26)
상기 배초향 분획물은 배초향 추출물로부터 분획되는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.The method of claim 1,
The baecho-hyang fraction is a health functional food composition for preventing or improving diabetes, characterized in that it is fractionated from baecho-hyang extract.
상기 배초향 추출물은 물, C1 내지 C4의 저급 알코올 및 저급 알코올 수용액으로 이루어진 군에서 선택된 용매로 추출되는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.3. The method of claim 2,
The baechohyang extract is a health functional food composition for preventing or improving diabetes, characterized in that it is extracted with a solvent selected from the group consisting of water, C1 to C4 lower alcohols and aqueous solutions of lower alcohols.
상기 배초향 추출물은 배초향 및 용매를 1 : 10의 부피비로 추출하는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.3. The method of claim 2,
The baechohyang extract is a health functional food composition for preventing or improving diabetes, characterized in that the baechohyang and solvent are extracted in a volume ratio of 1:10.
상기 배초향 추출물은 배초향의 잎, 줄기, 뿌리, 꽃 및 열매로 이루어진 군에서 선택된 부위에서 추출되는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.3. The method of claim 2,
The baechohyang extract is a health functional food composition for preventing or improving diabetes, characterized in that it is extracted from a portion selected from the group consisting of leaves, stems, roots, flowers and fruits of baechohyang.
상기 배초향 분획물은 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 클로로포름, 헥산 및 에틸아세테이트로 이루어진 군에서 선택된 용매로 분획되는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.The method of claim 1,
The baecho flavor fraction is a health functional food composition for preventing or improving diabetes, characterized in that it is fractionated with a solvent selected from the group consisting of water, C1 to C4 lower alcohol, lower alcohol aqueous solution, chloroform, hexane and ethyl acetate.
상기 배초향 분획물은 에틸아세테이트 및 부탄올 분획물인 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.7. The method of claim 6,
The baecho-hyang fraction is a health functional food composition for preventing or improving diabetes, characterized in that it is an ethyl acetate and butanol fraction.
상기 배초향 분획물은 알파-글루코시데이즈(α-glucosidase)의 활성을 억제시키는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물.The method of claim 1,
The baecho-hyang fraction is a health functional food composition for preventing or improving diabetes, characterized in that it inhibits the activity of alpha-glucosidase.
상기 배초향 분획물은 배초향 추출물로부터 분획되는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.10. The method of claim 9,
The baechohyang fraction is a pharmaceutical composition for preventing or treating diabetes, characterized in that it is fractionated from the baechohyang extract.
상기 배초향 추출물은 물, C1 내지 C4의 저급 알코올 및 저급 알코올 수용액으로 이루어진 군에서 선택된 용매로 추출되는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.11. The method of claim 10,
The baechohyang extract is a pharmaceutical composition for preventing or treating diabetes, characterized in that it is extracted with a solvent selected from the group consisting of water, C1 to C4 lower alcohols and aqueous solutions of lower alcohols.
상기 배초향 추출물은 배초향 및 용매를 1 : 10의 부피비로 추출하는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.11. The method of claim 10,
The baechohyang extract is a pharmaceutical composition for preventing or treating diabetes, characterized in that the baechohyang and solvent are extracted in a volume ratio of 1:10.
상기 배초향 추출물은 배초향의 잎, 줄기, 뿌리, 꽃 및 열매로 이루어진 군에서 선택된 부위에서 추출되는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.11. The method of claim 10,
The baechohyang extract is a pharmaceutical composition for preventing or treating diabetes, characterized in that it is extracted from a site selected from the group consisting of leaves, stems, roots, flowers and fruits of baechohyang.
상기 배초향 분획물은 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 클로로포름, 헥산 및 에틸아세테이트로 이루어진 군에서 선택된 용매로 분획되는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.10. The method of claim 9,
The baecho flavor fraction is a pharmaceutical composition for preventing or treating diabetes, characterized in that it is fractionated with a solvent selected from the group consisting of water, C1 to C4 lower alcohol, lower alcohol aqueous solution, chloroform, hexane and ethyl acetate.
상기 배초향 분획물은 에틸아세테이트 및 부탄올 분획물인 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.15. The method of claim 14,
The baechohyang fraction is a pharmaceutical composition for preventing or treating diabetes, characterized in that the ethyl acetate and butanol fraction.
상기 배초향 분획물은 알파-글루코시데이즈(α-glucosidase)의 활성을 억제시키는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물.10. The method of claim 9,
The baechohyang fraction is a pharmaceutical composition for preventing or treating diabetes, characterized in that it inhibits the activity of alpha-glucosidase.
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병 예방 또는 개선용 건강기능식품 조성물의 제조 방법.1) drying baechohyang ( Agastache rugosa );
2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) A method of preparing a health functional food composition for preventing or improving diabetes, comprising the step of fractionating the baechohyang extract of step 2) with a fractionation solvent.
상기 추출용매는 물, C1 내지 C4의 저급 알코올 및 저급 알코올 수용액인 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물의 제조 방법.18. The method of claim 17,
The extraction solvent is water, a C1 to C4 lower alcohol and a method for producing a health functional food composition for preventing or improving diabetes, characterized in that the aqueous solution of the lower alcohol.
상기 배초향 추출물은 배초향 및 용매를 1 : 10의 부피비로 추출하는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물의 제조 방법.18. The method of claim 17,
The baechohyang extract is a method of manufacturing a health functional food composition for preventing or improving diabetes, characterized in that extracting baechohyang and solvent in a volume ratio of 1:10.
상기 배초향 추출물은 배초향의 잎, 줄기, 뿌리, 꽃 및 열매로 이루어진 군에서 선택된 부위에서 추출되는 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물의 제조 방법.18. The method of claim 17,
The method for producing a health functional food composition for preventing or improving diabetes, characterized in that the extract is extracted from a portion selected from the group consisting of leaves, stems, roots, flowers and fruits of baechohyang.
상기 분획용매는 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 클로로포름, 헥산 및 에틸아세테이트로 이루어진 군에서 선택된 용매인 것을 특징으로 하는 당뇨병 예방 또는 개선용 건강기능식품 조성물의 제조 방법.18. The method of claim 17,
The fractionation solvent is water, C1 to C4 lower alcohol, lower alcohol aqueous solution, chloroform, hexane and ethyl acetate method for preventing or improving diabetes, characterized in that the solvent selected from the group consisting of a method of manufacturing a health functional food composition.
2) 상기 단계 1)의 건조된 배초향을 추출용매로 추출하는 단계; 및
3) 상기 단계 2)의 배초향 추출물을 분획용매로 분획하는 단계;를 포함하는 당뇨병 예방 또는 치료용 약학적 조성물의 제조 방법.1) drying baechohyang ( Agastache rugosa );
2) extracting the dried baecho flavor of step 1) with an extraction solvent; and
3) A method of preparing a pharmaceutical composition for preventing or treating diabetes, comprising a; fractionating the baechohyang extract of step 2) with a fractionation solvent.
상기 추출용매는 물, C1 내지 C4의 저급 알코올 및 저급 알코올 수용액인 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물의 제조 방법.23. The method of claim 22,
The extraction solvent is water, a C1 to C4 lower alcohol, and a method for producing a pharmaceutical composition for preventing or treating diabetes, characterized in that the aqueous solution of the lower alcohol.
상기 배초향 추출물은 배초향 및 용매를 1 : 10의 부피비로 추출하는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물의 제조 방법.23. The method of claim 22,
The baechohyang extract is a method of manufacturing a pharmaceutical composition for preventing or treating diabetes, characterized in that extracting baechohyang and a solvent in a volume ratio of 1:10.
상기 배초향 추출물은 배초향의 잎, 줄기, 뿌리, 꽃 및 열매로 이루어진 군에서 선택된 부위에서 추출되는 것을 특징으로 하는 당뇨병 예방 또는 치료용 약학적 조성물의 제조 방법.23. The method of claim 22,
The method for producing a pharmaceutical composition for preventing or treating diabetes, characterized in that the extract is extracted from a portion selected from the group consisting of leaves, stems, roots, flowers and fruits of the baechohyang extract.
상기 분획용매는 물, C1 내지 C4의 저급 알코올, 저급 알코올 수용액, 클로로포름, 헥산 및 에틸아세테이트로 이루어진 군에서 선택된 용매인 것을 특징으로 하는 예방 또는 치료용 약학적 조성물의 제조 방법.23. The method of claim 22,
The fractionation solvent is water, a C1 to C4 lower alcohol, an aqueous solution of lower alcohol, chloroform, hexane, and a method for producing a pharmaceutical composition for treatment, characterized in that the solvent selected from the group consisting of ethyl acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200174316A KR20220084641A (en) | 2020-12-14 | 2020-12-14 | Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200174316A KR20220084641A (en) | 2020-12-14 | 2020-12-14 | Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220084641A true KR20220084641A (en) | 2022-06-21 |
Family
ID=82221161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200174316A KR20220084641A (en) | 2020-12-14 | 2020-12-14 | Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220084641A (en) |
-
2020
- 2020-12-14 KR KR1020200174316A patent/KR20220084641A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
| KR101427784B1 (en) | An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients | |
| KR101976941B1 (en) | Composition comprising an extract of Elaeagnus umbellata for preventing and treating diabetes mellitus | |
| KR101226824B1 (en) | A composition comprising the extract of Sorghum bicolor L. Moench as an active ingredient for preventing and treating inflammatory disease | |
| KR101616811B1 (en) | Composition for treating diabete and diabete-induced complication containing an extract from Agrimonia pilosa | |
| EP2187769B1 (en) | Foodstuff of tablets or capsules | |
| KR102644808B1 (en) | Composition for preventing, ameliorating or treating metabolic disease comprising leaf extract of new pepper cultivar as effective component | |
| KR20220041735A (en) | Hypoglycemic composition comprising leaf extract of new pepper cultivar as effective component | |
| KR20220084641A (en) | Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient | |
| KR20220085352A (en) | Composition for preventing or treating diabetes containing Agastache rugosa fraction as an active ingredient | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR101134781B1 (en) | Composition comprising an the extract of Allium fistulosum L. for preventing and treating diabetes mellitus | |
| KR20210074865A (en) | Pharmaceutical composition for preventing or treating diabetes, including extract of fermented tea leaves | |
| KR101222779B1 (en) | A composition comprising the extract of Barnyardgrass as an active ingredient for preventing and treating inflammatory disease | |
| KR101226881B1 (en) | A composition comprising the extract of Proso millet as an active ingredient for preventing and treating inflammatory disease | |
| KR20050003665A (en) | Composition comprising an extract of Peucedanum japonicum for preventing and treating diabetes | |
| KR20220087295A (en) | Extract of Ligularia fischeriof as α-glucosidase inhibitor | |
| KR102266271B1 (en) | Composition for preventing or treating diabetes containing extract of Ixeris strigosa | |
| KR101799002B1 (en) | Composition for anti-diabetic comprising extract mixture of silkworm, persimmon peel and Schizandra chinensis as effective component | |
| KR20080054121A (en) | Composition containing extracts of glycyrrhizin radix praepara or compounds isolated therefrom for the blood glucose-lowering effect | |
| KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
| KR20230158317A (en) | Composition for the prevention or treatment of degenerative neurological diseases, comprising the extract of Sasa quelpaertensis as an active ingredient | |
| KR20230158318A (en) | Composition for the prevention or treatment of degenerative neurological diseases, comprising the extract of Sasa borealis as an active ingredient | |
| KR100526626B1 (en) | Anti-diabetic drug containing alcohol extract of Panax ginseng leaves | |
| KR20210041935A (en) | Health Food Composition For Prevention And Treatment Of Chronic Obstructive Pulmonary Disease Comprising Complex of Lilium Extract and Lespedeza Cuneata Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X601 | Decision of rejection after re-examination |